DBV Technologies S.A.

NasdaqCM:DBVT Aktierapport

Börsvärde: US$973.8m

DBV Technologies Balansräkning Hälsa

Finansiell hälsa kriterier kontrolleras 5/6

DBV Technologies har ett totalt eget kapital på $207.9M och en total skuld på $0.0 vilket ger sin skuldsättningsgrad till 0%. Dess totala tillgångar och totala skulder är $266.4M respektive $58.5M.

Viktig information

0%

Skuldsättning i förhållande till eget kapital

US$0

Skuld

Räntetäckningsgradn/a
KontanterUS$229.20m
Eget kapitalUS$207.90m
Summa skulderUS$58.50m
Totala tillgångarUS$266.40m

Nya uppdateringar om finansiell hälsa

Recent updates

Seeking Alpha • Sep 21

FDA puts partial clinical hold on a DBT Technologies peanut allergy patch phase 3 trial

French biotech DBV Technologies (NASDAQ:DBVT) on Wednesday said the U.S. FDA had put a partial clinical hold on its phase 3 clinical study evaluating its Viaskin Peanut patch for the treatment of peanut allergy in children aged 4 through 7. The FDA specified certain changes to elements of the protocol of the trial, called VITESSE. "Within the FDA’s communication, the modifications address design elements, including the statistical analysis of adhesion, minimum daily wear time and technical alignments in methods of categorizing data, to meet study objectives as well as the total number of trial participants on active treatment," DBVT said in a statement. The company had not yet begun the screening or recruitment of subjects in the study. DBVT said the partial clinical hold was only for the VITESSE trial and did not impact any other ongoing clinical studies. U.S.-listed shares of DBVT earlier closed +4.3% at $2.21.
Seeking Alpha • Aug 01

DBV Technologies GAAP EPS of -$0.35 misses by $0.03, revenue of $1.53M beats by $0.29M

DBV Technologies press release (NASDAQ:DBVT): Q2 GAAP EPS of -$0.35 misses by $0.03. Revenue of $1.53M beats by $0.29M. Shares +3.19% AH.
Seeking Alpha • Jul 07

DBV Technologies: Good Data, Plenty Of Cash And Regulatory Uncertainty

DBV Technologies is a French company traded on Nasdaq which is developing treatments for food allergies. Their technology is a patch that delivers a very small daily dose of the allergen to desensitize the patient. The company previously received a CRL due to issues with the adhesion properties of their patch. The Phase 3 EPITOPE trial met the primary endpoint with a good safety profile. FDA feedback on the regulatory path is the next critical catalyst for the company. DBV Technologies (DBVT) is developing an epicutaneous (on the skin) delivery system for the treatment of food allergies including peanuts and milk. After completing a Phase 3 trial in children ages 4-11, the company received a CRL from the FDA for their Viaskin peanut patch due to concerns about patch adhesion. The company redesigned the patch and will need to run a new Phase 3 trial using the modified patch for this age group. Recently, using the unmodified patch, the EPITOPE study met the primary endpoint in children ages 1-4. DBV Technologies is well capitalized after a recent raise that occurred after the EPITOPE readout. There is considerable uncertainty about the regulatory path but longer term these assets, if approved have significant value. Peanut Allergies and Treatment Options There are more than one million children in the US with peanut allergies. The prevalence in babies is increasing and as many as 5% of babies have a peanut allergy. Avoidance of peanuts is the primary strategy but accidental exposure can result in severe reactions. Allergy treatments gradually increase the quantity of allergen that a child is exposed to. The goal of treatment is to desensitize the child and increase the quantity of peanut that elicits an allergic reaction. There are no FDA-approved treatments for peanut allergies in children ages 1-3. At age 4, children would become eligible for Palforzia which is an oral immunotherapy. It is newly approved and can only be prescribed by a trained allergist and requires an FDA mandated risk mitigation plan due to the risk of anaphylaxis. In the Palforzia program, under the supervision of a trained physician, children ingest increasing amounts of peanut protein. Dose escalation occurs in a certified physician’s office. At dose escalation, 67 % of patients reported abdominal pain, 36.5% experienced vomiting, 32% reported nausea and 31% reported oral itching. There was a 9.4 % rate of anaphylaxis during dose escalation and 8.7% during maintenance dosing. At the end of treatment, 67% of Palforzia patients could tolerate a 600 mg dose of peanuts. (600 mg is approximately 2 peanuts). The EPITOPE study met the primary endpoint Toddlers aged 1-3 who have a peanut allergy were enrolled in the clinical trial. On a daily basis, their caregivers applied a Viaskin peanut patch. The patch at the highest dose contains 250 micrograms of peanut protein which is a very, very small amount of peanut protein. (A microgram is one thousandth of an mg.) The EPITOPE trial was one year in duration. 244 toddlers received treatment and 118 received placebo. At baseline and at the end of treatment, toddlers received a food challenge to determine their eliciting dose. The eliciting dose is the amount of peanut that causes allergic symptoms. At the end of treatment, patients who were successfully treated made the improvements shown in the chart below. Before Treatment After Treatment Eliciting dose less than or equal to 10 mg Eliciting dose greater than or equal to 300 mg Eliciting dose greater than 10 mg Eliciting dose greater than or equal to 1000 mg Source: DBV Technologies 67% of children treated met the "success" response criteria at 12 months. In comparison, 33.5 % of placebo treated children met the endpoint. (Note: The placebo response was likely a result of a self resolving peanut allergy.) This result was statistically significant and the primary endpoint was met. In the trial, there was one SAE which was swelling around the eye. The most common side effect was a reaction at the site where the patch was applied. 22.5 % of the children experienced a site reaction that was severe as compared to 8.5% of placebo patients. These reactions decreased during the one year treatment period. Eight children discontinued treatment due to side effects. Four children (1.6%) treated with Viaskin Peanut experienced an anaphylactic reaction that was determined to be or may have been related to treatment. None of these anaphylactic reactions were serious. Three of these reactions resolved with epinephrine and one without epinephrine. A long term open label extension study is underway. Revenue Projections

Analys av finansiell ställning

Kortfristiga skulder: DBVT s kortfristiga tillgångar ( $246.7M ) överstiger dess kortfristiga skulder ( $51.8M ).

Långfristiga skulder: DBVT s kortfristiga tillgångar ( $246.7M ) överstiger dess långfristiga skulder ( $6.7M ).

Skuld till eget kapital Historik och analys

Skuldnivå: DBVT är skuldfri.

Minska skulden: DBVT har inga skulder jämfört med för 5 år sedan när dess skuldsättningsgrad var 0.6%.

Balansräkning

Analys av kontantbanan

För företag som i genomsnitt har gått med förlust tidigare bedömer vi om de har minst 1 års kassaflöde.

Stabil Cash Runway: DBVT har tillräckligt med cash runway i mer än ett år baserat på dess nuvarande fria kassaflöde.

Prognos Cash Runway: DBVT har mindre än ett år av kontanter om det fria kassaflödet fortsätter att växa i historiska takter på 6.8 % varje år.

Upptäck friska företag

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/07/08 11:55
Aktiekurs vid dagens slut2026/07/08 00:00
Intäkter2026/03/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

DBV Technologies S.A. bevakas av 16 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Tazeen AhmadBofA Global Research
Kristen KluskaCantor Fitzgerald & Co.
Jonathan WollebenCitizens JMP Securities, LLC